These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 27064194)

  • 41. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
    Paine CS
    Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
    [No Abstract]   [Full Text] [Related]  

  • 42. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
    Falit BP; Singh SC; Brennan TA
    Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
    [TBL] [Abstract][Full Text] [Related]  

  • 43. What do pharmaceuticals really cost in the long run?
    Lakdawalla D; MacEwan JP; Dubois R; Westrich K; Berdud M; Towse A
    Am J Manag Care; 2017 Aug; 23(8):488-493. PubMed ID: 29087143
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of Evergreened Reformulations on Medicaid Expenditures and Patient Access from 2008 to 2016.
    Dickson S
    J Manag Care Spec Pharm; 2019 Jul; 25(7):780-792. PubMed ID: 30799664
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The balance between innovation and competition: the Hatch-Waxman Act, the 2003 Amendments, and beyond.
    Kelly C
    Food Drug Law J; 2011; 66(3):417-78, iii. PubMed ID: 24505856
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Factors that have an Impact on Abbreviated New Drug Application (ANDA) Submissions.
    Wittayanukorn S; Rosenberg M; Schick A; Hu M; Wang Z; Babiskin A; Lionberger R; Zhao L
    Ther Innov Regul Sci; 2020 Nov; 54(6):1372-1381. PubMed ID: 32495310
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Market exclusivity for top-selling pharmaceuticals: too long, too short, or just right?
    Downing NS
    JAMA Intern Med; 2015 Apr; 175(4):637-8. PubMed ID: 25664529
    [No Abstract]   [Full Text] [Related]  

  • 48. Trends in Use and Expenditures for Brand-name Statins After Introduction of Generic Statins in the US, 2002-2018.
    Lin SY; Baumann K; Zhou C; Zhou W; Cuellar AE; Xue H
    JAMA Netw Open; 2021 Nov; 4(11):e2135371. PubMed ID: 34807258
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The importance of being first: evidence from Canadian generic pharmaceuticals.
    Hollis A
    Health Econ; 2002 Dec; 11(8):723-34. PubMed ID: 12457372
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021.
    Gupta R; Morten CJ; Zhu AY; Ramachandran R; Shah ND; Ross JS
    JAMA Health Forum; 2022 May; 3(5):e221096. PubMed ID: 35977259
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Citizen's Pathway Gone Astray - Delaying Competition from Generic Drugs.
    Feldman R; Wang C
    N Engl J Med; 2017 Apr; 376(16):1499-1501. PubMed ID: 28248550
    [No Abstract]   [Full Text] [Related]  

  • 52. Targeting Unconscionable Prescription-Drug Prices - Maryland's Anti-Price-Gouging Law.
    Greene JA; Padula WV
    N Engl J Med; 2017 Jul; 377(2):101-103. PubMed ID: 28591520
    [No Abstract]   [Full Text] [Related]  

  • 53. Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical.
    Kong Y
    Health Econ; 2009 May; 18(5):591-606. PubMed ID: 18816580
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Price regulation and generic competition in the pharmaceutical market.
    Dalen DM; Strøm S; Haabeth T
    Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of generic drug competition on the price of prescription drugs in Ontario.
    Lexchin J
    CMAJ; 1993 Jan; 148(1):35-8. PubMed ID: 8439888
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Impact of Price-cap Regulations on Exit by Generic Pharmaceutical Firms.
    Zhang W; Guh D; Sun H; Marra CA; Lynd LD; Anis AH
    Med Care; 2016 Sep; 54(9):884-90. PubMed ID: 27213540
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Competition in prescription drug markets: the roles of trademarks, advertising, and generic names.
    Feldman R; Lobo F
    Eur J Health Econ; 2013 Aug; 14(4):667-75. PubMed ID: 22815099
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interrupted time-series analysis of the impact of generic market entry of antineoplastic products in China.
    Guan X; Tian Y; Ross-Degnan D; Man C; Shi L
    BMJ Open; 2018 Jul; 8(7):e022328. PubMed ID: 30012792
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The diffusion of generics after patent expiry in Germany.
    Fischer KE; Stargardt T
    Eur J Health Econ; 2016 Nov; 17(8):1027-1040. PubMed ID: 26573841
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Correcting Hatch-Waxman.
    Fernandes M
    Health Aff (Millwood); 2008; 27(3):902-3; author reply 903. PubMed ID: 18475000
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.